FAQ/Help |
Calendar |
Search |
Today's Posts |
04-25-2011, 08:04 PM | #1 | ||
|
|||
Senior Member
|
Positive Results With Extended-Release Carbidopa-Levodopa
http://www.medscape.com/viewarticle/...s%3Fsrc%3Dstfb |
||
Reply With Quote |
04-28-2011, 01:23 AM | #2 | |||
|
||||
In Remembrance
|
Quote:
i used to go to KU - until medicaid policy changed? thank you loulou
__________________
with much love, lou_lou . . by . , on Flickr pd documentary - part 2 and 3 . . Resolve to be tender with the young, compassionate with the aged, sympathetic with the striving, and tolerant with the weak and the wrong. Sometime in your life you will have been all of these. |
|||
Reply With Quote |
05-03-2011, 09:58 AM | #3 | |||
|
||||
Senior Member
|
I don't know if it's too early in the morning, and I admit that I have not been able to keep up with all that has been posted on thhis new therapy. I have a question or two:
The article/interview says: IPX066 contains both sustained- and immediate-release carbidopa-levodopa, so it can rapidly attain therapeutic levodopa concentrations and maintain them over time in early studies up to 6 hours. These results (I think) were obtained from early diagnosed patients - right? They had been treated only a short t ime. Then there was testing with Advanced patients. It reported: The ADVANCE-PD study enrolled 471 subjects on a stable regimen of immediate-release carbidopa-levodopa, according to the company release in March. All were first entered into a dose-adjustment phase of immediate-release formulation followed by conversion to IPX066. They were then randomized to either the immediate-release formulation or IPX066 for the blinded portion of the study. All those converted to IPX066 had a reduction from baseline of more than 2 hours in off time during waking hours, and the reduction was maintained in the group subsequently randomized to the sustained-release formulation for the blinded portion. In contrast, among those switched to IPX066 and then back to the immediate-release formulation for the double-blind phase, off time worsened again by 1 hour . During the double-blind phase, "on" time without dyskinesia was improved by 1.9 hours with IPX066 vs 0.8 hours with the immediate-release formulation. Improvements with the extended-release formulation were also seen on the UPDRS, Clinical Global Impression of Change, and the Patient Global Impression of Change Questions: Would this one pill be taken in lieu of present medication regime? |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD), Phase III results | Parkinson's Disease | |||
differences between generic carbidopa/levodopa cr | Parkinson's Disease | |||
911 - levodopa carbidopa and tactacardia | Parkinson's Disease | |||
are you taking your CARBIDOPA/LEVODOPA SUSTAINED-RELEASE Correctly? | Parkinson's Disease | |||
Dizzy from Carbidopa-Levodopa | Parkinson's Disease |